The present invention relates to a process for manufacture of 2-nitroimino heterocyclic compounds and intermediates thereof. More particularly, the present invention relates to a convenient manufacturing process for preparation of 2-nitroimino imidazolidine compounds.

This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.

This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.

Provided is a catalase inhibitor comprising a compound represented by formula (I): ##STR00001##
wherein R.sub.1 to R.sub.4 independently represent a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a carbonyl group, or a hydrocarbon group having 1 to 4 carbon atoms, wherein the hydrocarbon group may have at least one substituent selected from the group consisting of a halogen atom, an amino group, a hydroxyl group and a carbonyl group; and X.sup. represents an anionic chemical species.

The invention provides methods for producing analgesia in an animal comprising administering to the animal a compound of the formula Ia, Ib, Ic, and Id:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables A, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.x, L, X, Y, and Z have the meaning as described herein.

The invention provides methods for producing analgesia in an animal comprising administering to the animal a compound of the formula Ia, Ib, Ic, and Id:

##STR00001##

and pharmaceutically acceptable salts thereof, wherein the variables A, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.x, L, X, Y, and Z have the meaning as described herein.

Provided is a catalase inhibitor comprising a compound represented by formula (I):

##STR00001##

wherein R.sub.1 to R.sub.4 independently represent a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a carbonyl group, or a hydrocarbon group having 1 to 4 carbon atoms, wherein the hydrocarbon group may have at least one substituent selected from the group consisting of a halogen atom, an amino group, a hydroxyl group and a carbonyl group; and X.sup. represents an anionic chemical species.

This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.

This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.

An organic electroluminescence device of an embodiment includes a first electrode, a hole transport region disposed on the first electrode, an emission layer disposed on the hole transport region, an electron transport region disposed on the emission layer, and a second electrode disposed on the electron transport region, wherein the hole transport region includes a diamine compound represented by Formula 1, thereby showing high emission efficiency: ##STR00001##